What is Chronic Severe Gout?
A subpopulation of gout patients suffers from chronic severe gout, which is typically characterized by a high burden of tophi (inflammatory nodules of crystalized uric acid) that do not respond to existing medications.

Patients with chronic severe gout experience recurrent and highly debilitating flares, gouty arthritis, and significantly reduced quality of life.

What is Chronic Severe Gout?
A subpopulation of gout patients suffers from chronic severe gout, which is typically characterized by a high burden of tophi (inflammatory nodules of crystalized uric acid) that do not respond to existing medications.

Patients with chronic severe gout experience recurrent and highly debilitating flares, gouty arthritis, and significantly reduced quality of life.

Oral gout medications are not effective at ridding patients of established tophi.

In the U.S., individuals with severe gout have up to a 33-fold increase in comorbidities5

Individuals with tophi have up to a 3-fold increase in mortality risk compared to patients with gout6

The increased morbidity and mortality of patients with chronic severe gout are associated with tophi, which are not effectively addressed by currently available treatments.

SEL-212

Selecta’s SEL-212 is an investigational medicine in Phase 2 clinical development designed to address the acute symptoms of chronic severe gout by dramatically lowering serum uric acid to levels conducive to the resolution of tophi while avoiding adverse reactions due to immunogenicity.

SEL-212

Designed to:
✓ Drastically and durably lower serum uric acid to levels conducive to rapid tophi dissolution
✓ Avoid immunogenicity normally associated with uricase enzyme therapy, which can comprise its safety and effectiveness
✓ Reduce incidence of gout flares following treatment initiation

1 https://www.hopkinsarthritis.org/arthritis-info/gout/clinical-presentation-of-gout/